Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials.
about
The promise of bacteriophage therapy for Burkholderia cepacia complex respiratory infectionsAdvances in bacteriophage-mediated control of plant pathogensBacteriophage Procurement for Therapeutic PurposesBacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current statusPhage Therapy: a Step Forward in the Treatment of Pseudomonas aeruginosa InfectionsPhage cocktails and the future of phage therapyBacteriophages and phage-derived proteins--application approachesPseudomonas aeruginosa keratitis in mice: effects of topical bacteriophage KPP12 administrationSynergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureusStrain Specific Phage Treatment for Staphylococcus aureus Infection Is Influenced by Host Immunity and Site of InfectionApplication of Bacteriophage-containing Aerosol against Nosocomial Transmission of Carbapenem-Resistant Acinetobacter baumannii in an Intensive Care UnitBacteriophage therapy of a Vibrio parahaemolyticus infection caused by a multiple-antibiotic-resistant O3:K6 pandemic clinical strain.Romulus and Remus, two phage isolates representing a distinct clade within the Twortlikevirus genus, display suitable properties for phage therapy applicationsSelection and characterization of a candidate therapeutic bacteriophage that lyses the Escherichia coli O104:H4 strain from the 2011 outbreak in GermanyPhage therapy--constraints and possibilities.Characterization of JG024, a pseudomonas aeruginosa PB1-like broad host range phage under simulated infection conditions.Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections.Characterization, sequencing and comparative genomic analysis of vB_AbaM-IME-AB2, a novel lytic bacteriophage that infects multidrug-resistant Acinetobacter baumannii clinical isolatesContrasted coevolutionary dynamics between a bacterial pathogen and its bacteriophages.Microbiological and molecular assessment of bacteriophage ISP for the control of Staphylococcus aureusBacteriophages of Pseudomonas.Genomic and proteomic characterization of the broad-host-range Salmonella phage PVP-SE1: creation of a new phage genus.Phage treatment of human infections.CIM(®) monolithic anion-exchange chromatography as a useful alternative to CsCl gradient purification of bacteriophage particles.Isolation and partial characterization of bacteriophages infecting Pseudomonas syringae pv. actinidiae, causal agent of kiwifruit bacterial canker.Experimental phage therapy of burn wound infection: difficult first stepsEvolution of Pseudomonas aeruginosa virulence as a result of phage predation.Genomic characterization of JG068, a novel virulent podovirus active against Burkholderia cenocepacia.Pseudomonas aeruginosa adaptation to lungs of cystic fibrosis patients leads to lowered resistance to phage and protist enemiesPopulation dynamics of a Salmonella lytic phage and its host: implications of the host bacterial growth rate in modellingRemoval of endotoxins from bacteriophage preparations by extraction with organic solvents.Characterization of newly isolated lytic bacteriophages active against Acinetobacter baumannii.Characterization of the Newly Isolated Lytic Bacteriophages KTN6 and KT28 and Their Efficacy against Pseudomonas aeruginosa Biofilm.The isolation and characterization of two Stenotrophomonas maltophilia bacteriophages capable of cross-taxonomic order infectivity.In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients.Pseudomonas biofilms, cystic fibrosis, and phage: a silver lining?Bacteriophages and phage-inspired nanocarriers for targeted delivery of therapeutic cargos.Phage ΦPan70, a Putative Temperate Phage, Controls Pseudomonas aeruginosa in Planktonic, Biofilm and Burn Mouse Model AssaysEfficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain producing CTX-M-15A Partially Purified Acinetobacter baumannii Phage Preparation Exhibits no Cytotoxicity in 3T3 Mouse Fibroblast Cells.
P2860
Q21131311-4825DE7A-61BC-463A-919F-EDF3447BD264Q21296665-121E2DA4-D000-4EDE-A30E-4D78B292B5EEQ26738479-803CDD3D-A47A-40DC-BF76-82C544E2C6C1Q26799417-9532D90F-5BE5-4390-A995-12A35D1036F6Q26823401-E51B95E3-1045-48F6-910B-64C5DE9F3EA2Q26995797-904674BC-BCF1-4982-A3A4-46290D6E1766Q28082731-D656CB30-8A49-48CE-B8B7-634C8D3889FBQ28484466-FA8A3533-F69C-443B-A24B-740252ECF812Q28485429-F2503ED5-73CD-41BB-8381-CFD476561472Q28546694-B57A60CA-D3C9-4828-BA0A-555A404475C0Q28555082-B0B576EC-5977-4B87-92F7-F91E08F25127Q30359301-99E9D8E1-2C7A-4023-B001-D9A30CDA4B27Q30585271-9FD32CE0-9A9B-40D8-826A-F77C6AA6C964Q33405088-3AAB227E-7007-407D-98EC-5CCE570801DFQ33667556-B76367AD-9200-433F-98C6-D75D6C3F9030Q33756667-4883CD32-95D5-4021-B260-A4FEB9445F0BQ33798541-CE1901FA-9863-4596-8E75-5501E916C3D9Q33890690-B09D4C3C-D356-452B-A694-FCCC6B5870AAQ34002414-09758BCB-3F31-4F77-AD1A-0627537BE945Q34023508-CA241324-604F-48FA-8F4C-1A0416DDA14FQ34126072-E58056BF-DCA1-444F-A9C0-070395673C2EQ34210551-69EAA451-DF7F-42AC-A12F-3106A415554EQ34254407-D8DDDEBC-B72D-49B6-B572-D85627CC52F8Q34306994-21F575E3-40F6-47DA-BB09-5DCD92A92A7AQ34419366-32BA4D63-CD03-40E1-92AD-85466F315FD4Q34420348-8BD280A9-D84B-4E01-A2BE-484A25F2E474Q34871061-AF244DA3-BE1B-4A4D-8C59-342FB00A169FQ34974472-CD1FDCA9-6A83-4DD1-8006-73B4F37A3048Q34999578-FC0A9B81-65BB-4DF7-B2B9-4CE5A7C9E85AQ35211072-56263194-ED94-4D28-B992-B5F02055118FQ35219507-8B76BF5B-07F2-4C4D-9A1E-18E4546EA90BQ35222732-013054E1-9082-46DD-908B-D97AE69EB14CQ35634231-46D4B976-F02A-45C6-9BC5-E30E76E140C8Q35763512-7B652C06-987F-4953-9AA7-5DFB4C5044CEQ35780029-AC386FD1-A828-4E27-A39C-9B9B6FE9836DQ35878716-8B48A0D6-3CD0-40E2-A5F8-EAA441B7D47AQ35963673-1CA3AAC3-4341-4E1E-9CC8-BA3C541D7089Q36076253-0A4E891D-1768-4DA8-85E4-1A6FC23269C8Q36086395-230157EC-1E8E-470D-BB89-D2940160673CQ36106493-BE3A4452-F69F-4B8F-B605-3038E5E09A69
P2860
Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Quality-controlled small-scale ...... use in human clinical trials.
@ast
Quality-controlled small-scale ...... use in human clinical trials.
@en
type
label
Quality-controlled small-scale ...... use in human clinical trials.
@ast
Quality-controlled small-scale ...... use in human clinical trials.
@en
prefLabel
Quality-controlled small-scale ...... use in human clinical trials.
@ast
Quality-controlled small-scale ...... use in human clinical trials.
@en
P2093
P2860
P50
P1433
P1476
Quality-controlled small-scale ...... use in human clinical trials.
@en
P2093
Daniel De Vos
Gilbert Verbeken
Guido Volckaert
Gunther Verween
Luc Van Parys
Marina Tediashvili
Martin Zizi
Maya Merabishvili
Nino Lashkhi
P2860
P356
10.1371/JOURNAL.PONE.0004944
P407
P577
2009-03-20T00:00:00Z